Explore more publications!
Africa News Currents
Got News to Share?

Africa News Currents: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa News Currents.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on October 22, 2025

Instalação de Medicamentos Estéreis da Curia Nomeada Fabricante do Ano de Massachusetts
October 22, 2025

Instalação de Medicamentos Estéreis da Curia Nomeada Fabricante do Ano de Massachusetts

Indeterminate GlobeNewswire
โรงงานผลิตภัณฑ์ยาปลอดเชื้อ Curia ได้รับการเสนอชื่อให้เป็นผู้ผลิตแห่งปีของรัฐแมสซาชูเซตส์
October 22, 2025

โรงงานผลิตภัณฑ์ยาปลอดเชื้อ Curia ได้รับการเสนอชื่อให้เป็นผู้ผลิตแห่งปีของรัฐแมสซาชูเซตส์

Indeterminate GlobeNewswire
Curia Sterile Drug Product Facility 荣膺马萨诸塞州年度制造商称号
October 22, 2025

Curia Sterile Drug Product Facility 荣膺马萨诸塞州年度制造商称号

Indeterminate GlobeNewswire
Curia 無菌藥品生產設施榮膺麻省年度最佳製造商美譽
October 22, 2025

Curia 無菌藥品生產設施榮膺麻省年度最佳製造商美譽

Indeterminate GlobeNewswire
ADARx Pharmaceuticals Announces First Patient Dosed in Phase 3 STOP-HAE Clinical Trial and Orphan Drug Designation for ADX-324, a Long-Acting siRNA in Development for the Prophylactic Treatment of Hereditary Angioedema (HAE)
October 22, 2025

ADARx Pharmaceuticals Announces First Patient Dosed in Phase 3 STOP-HAE Clinical Trial and Orphan Drug Designation for ADX-324, a Long-Acting siRNA in Development for the Prophylactic Treatment of Hereditary Angioedema (HAE)

Indeterminate GlobeNewswire
SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum
October 22, 2025

SELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum

Indeterminate GlobeNewswire
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
October 22, 2025

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

Indeterminate GlobeNewswire
Taseko Announces Closing of Bought Deal Financing for Gross Proceeds of US$170 Million
October 22, 2025

Taseko Announces Closing of Bought Deal Financing for Gross Proceeds of US$170 Million

Indeterminate GlobeNewswire
Critical Metals Corp Appoints Rear Admiral Peter Stamatopoulos to its Advisory Board
October 22, 2025

Critical Metals Corp Appoints Rear Admiral Peter Stamatopoulos to its Advisory Board

Indeterminate GlobeNewswire
Prime Mining Closes Arrangement with Torex Gold
October 22, 2025

Prime Mining Closes Arrangement with Torex Gold

Indeterminate GlobeNewswire
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
October 22, 2025

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Indeterminate GlobeNewswire
Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek
October 22, 2025

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

Indeterminate GlobeNewswire
SONORO GOLD ANNOUNCES CLOSING OF OVERSUBSCRIBED $4 MILLION PRIVATE PLACEMENT
October 22, 2025

SONORO GOLD ANNOUNCES CLOSING OF OVERSUBSCRIBED $4 MILLION PRIVATE PLACEMENT

Indeterminate GlobeNewswire
NorthWest Copper Announces Results of 2025 AGM
October 22, 2025

NorthWest Copper Announces Results of 2025 AGM

Indeterminate GlobeNewswire
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
October 22, 2025

Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million

Indeterminate GlobeNewswire
Electra Therapeutics Announces First Patients Dosed in the SURPASS Phase 2/3 Pivotal Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
October 22, 2025

Electra Therapeutics Announces First Patients Dosed in the SURPASS Phase 2/3 Pivotal Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Indeterminate GlobeNewswire
Electra Therapeutics Receives FDA Breakthrough Therapy and EMA Priority Medicines Designations for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
October 22, 2025

Electra Therapeutics Receives FDA Breakthrough Therapy and EMA Priority Medicines Designations for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Indeterminate GlobeNewswire
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer
October 22, 2025

Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer

Indeterminate GlobeNewswire
MEXC Foundation Mobilizes Emergency Relief for Philippines Earthquakes
October 22, 2025

MEXC Foundation Mobilizes Emergency Relief for Philippines Earthquakes

Indeterminate GlobeNewswire
MEXC Q3 2025 Report Highlights Market Leadership Across New Listings, Security, and Ecosystem Growth
October 22, 2025

MEXC Q3 2025 Report Highlights Market Leadership Across New Listings, Security, and Ecosystem Growth

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions